Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314

Inclusion Criteria: 1. Patients aged ≥ 18 years 2. Patients diagnosed with COVID-19 infection and pneumonia 3. Patients who have voluntarily decided to participate in the study and signed the informed consent form If a patient cannot provide consent on his or her own, informed consent by a legally authorized representative may be obtained. Exclusion Criteria: 1. Patients with history of hypersensitivity to the study drug 2. Female patients, either who are or may be pregnant or who are breastfeeding, or female patients of child-bearing potential who are unable to use adequate contraception during the study 3. Patients who are deemed to ineligible to participate in the study for other reasons by the investigator